Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Steven D. Sorden"'
Autor:
Steven D. Sorden, Leslie E McPherson, Alok K. Sharma, Erica E Carroll, Thomas Larsen, Oliver C. Turner
Publikováno v:
Toxicologic Pathology. 49:569-580
Identification of test article–related microscopic findings in ocular toxicology studies requires a working knowledge of the artifacts and procedure-related or background findings commonly encountered in such studies. The objective of this article
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f49131b85cf72e4d2c9b6fb7f888fa36
https://doi.org/10.1177/0192623320966244
https://doi.org/10.1177/0192623320966244
Publikováno v:
Toxicologic Pathology. 49:537-543
The goal of this study was to develop methods for the evaluation of green fluorescent protein (GFP) and GFP transcript biodistribution in paraformaldehyde-fixed paraffin-embedded (PFPE) eye sections to assess the effectiveness of Adeno-associated vir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849f7793fa1487c5cedb964cbe979337
https://doi.org/10.1177/0192623320964804
https://doi.org/10.1177/0192623320964804
Autor:
Typhaine Lejeune, Brian Short, Jaqueline Brassard, Krishna Yekkala, Margarita M. Gruebbel, Cindy A. Farman, Bindu Bennet, Oliver C. Turner, Steven D. Sorden, Kenneth A Schafer, Elke-Astrid Atzpodien, Helen Booler, George L. Foley, Meg Ferrell Ramos
Publikováno v:
Toxicologic pathology. 50(2)
A Working Group of the Society of Toxicologic Pathology’s Scientific and Regulatory Policy Committee conducted a technical and scientific review of current practices relating to the fixation, trimming, and sectioning of the nonrodent eye to identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8534718ecfa0edfef4e0b09dec1d2a8
https://pubmed.ncbi.nlm.nih.gov/34693851
https://pubmed.ncbi.nlm.nih.gov/34693851
Publikováno v:
Toxicologic Pathology. 49:417-418
Dysfunction of the visual system remains a leading cause of human disability worldwide. Preclinical studies are a key component of efforts to develop drugs and devices to ameliorate visual impairment. Although new opportunities for the delivery of ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2bf25a42d2b1a525fc7a23e3d8d2929
https://doi.org/10.1177/0192623320986558
https://doi.org/10.1177/0192623320986558
Autor:
Natalie R Russell, Michael R. Elwell, Michael L. Pritt, Steven D. Sorden, Paul D. Cornwell, John L. Vahle, Manoj Bhaskaran
Publikováno v:
Toxicologic pathology. 46(4)
Inhibitors of Bruton’s tyrosine kinase (BTK) are under development as potential therapies for various autoimmune diseases. In repeat-dose toxicity studies, small-molecule BTK inhibitors (BTKi) have been reported to cause a constellation of histolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39f0ac36ae4cb2c3923c999b51e3701
https://pubmed.ncbi.nlm.nih.gov/29699458
https://pubmed.ncbi.nlm.nih.gov/29699458
The eye is susceptible to adverse toxic effects by direct application, inadvertent ocular contact, or systemic exposure to chemicals or their metabolites. Although the albino rat is a less than ideal model for ocular toxicity studies, it has gained p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1bb0fc6741ac044ff177c93b13f11d9
https://doi.org/10.1016/b978-0-12-391448-4.00016-2
https://doi.org/10.1016/b978-0-12-391448-4.00016-2
Autor:
Roger Alison, Julia F.M. Baker, Lise Bertrand, Pamela E. Blackshear, Brad Blankenship, Gary Boorman, Suzanne Botts, Michael Boyle, Alys Bradley, Danielle L. Brown, Mark F. Cesta, Vivian Chen, Phaedra Cole, Michelle C. Cora, Darlene Dixon, Dale G. Dunn, Johnnie J. Eighmy, Susan A. Elmore, Michael R. Elwell, Scot L. Eustis, Pierluigi Fant, Stacey L. Fossey, John R. Foster, Denzil Frost, Silvia Guionaud, D. Greg Hall, Gordon C. Hard, Adam Hargreaves, Ronald A. Herbert, Kyathanahalli S. Janardhan, Michael P. Jokinen, Ken Latimer, Joel R. Leininger, Régis Masson, Jenny McKay, Mark G. Mense, Rodney A. Miller, Shunji Nakatsuji, Arun R. Pandiri, Nicola Parry, Deepa B. Rao, Marlon C. Rebelatto, Amera K. Remick, Thomas J. Rosol, Aude Roulois, Melissa Schutten, John Curtis Seely, Alok K. Sharma, Steven D. Sorden, Catherine Sutcliffe, Andrew W. Suttie, Kathleen A. Szabo, Gregory S. Travlos, Takeki Uehara, John L. Vahle, Justin D. Vidal, Katharine M. Whitney, Jyoji Yamate, Katsuhiko Yoshitomi, Katsuhiko Yoshizawa, Bevin Zimmerman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fbc2cbcd3b2d821621dbb8fdbd177b3
https://doi.org/10.1016/b978-0-12-391448-4.00043-5
https://doi.org/10.1016/b978-0-12-391448-4.00043-5
Autor:
Günter Klöppel, Thomas Ryan, Jamie L. Blackbourne, Steven D. Sorden, Thomas J. Rosol, Thomas Pienkowski, John L. Vahle, Paul W. Snyder, Richard A. Byrd, Jennifer A. Martin
Publikováno v:
Toxicologic Pathology. 43:1004-1014
Clinical and nonclinical studies have implicated glucagon-like peptide-1 (GLP-1) receptor agonist therapy as a risk factor for acute pancreatitis in patients with type 2 diabetes. Therefore, it is critical to understand the effect that dulaglutide, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24dc33896c26140b314f0f3d6b268813
https://doi.org/10.1177/0192623315588999
https://doi.org/10.1177/0192623315588999
Autor:
Thomas J. Rosol, Thomas Ryan, Jamie L. Blackbourne, Steven D. Sorden, John L. Vahle, Ricardo Quander, John A. Wijsman, Richard LaRock, Jennifer A. Martin, Richard A. Byrd, Thomas Pienkowski, Holly W. Smith, Gerald G. Long
Publikováno v:
Endocrinology. 156:2417-2428
The tumorigenic potential of dulaglutide was evaluated in rats and transgenic mice. Rats were injected sc twice weekly for 93 weeks with dulaglutide 0, 0.05, 0.5, 1.5, or 5 mg/kg corresponding to 0, 0.5, 7, 20, and 58 times, respectively, the maximum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf05a45d550322893380cb5ee957415f
https://doi.org/10.1210/en.2014-1722
https://doi.org/10.1210/en.2014-1722
Autor:
Justyna Korczynska, Lemy Tsikna, Zoe Hughes-Thomas, Richard Haworth, Christopher J. Roberts, John Warrack, Steven D. Sorden, Irene Papanicolaou, Rodd Polsky, Eric Dobrzynski, Edit Kurali, Timothy Streit, Thomas Wilde, Jeffery J Prusakiewicz, Brian J Christian, Peter C. Adamson, T Michael Nork, Ian Richard Catchpole, Craig Struble, Caroline Sychterz, James Walford, Chi-Man Tang, Daniel Gibson, Ruud Verrijk, Paul E. Miller, Fiona Cook, Jos Smal
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society
A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery system were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month period following a single intravitreal (IVT) injection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9ca6065ba82c3a95211a3152eff24c
https://pubmed.ncbi.nlm.nih.gov/27810558
https://pubmed.ncbi.nlm.nih.gov/27810558